Skip to main content

Advertisement

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Article metrics

  • 537 Accesses

The original article was published in Arthritis Research & Therapy 2019 21:79

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1856-4

Following publication of the original article [1], the authors reported an error in Table 2. The data for ‘HAQ-DI response (MCID ≥ 0.3), n (%) / At week 52’ for the ‘Sarilumab 150 mg q2w + MTX’ and ‘Sarilumab 200 mg q2w + MTX’ groups should be 41 (50.6) and 37 (46.3), respectively (last row, last two entries of the table).

The corrected table is given below.

Table 2 Efficacy results (mITT population)

Reference

  1. 1.

    Tanaka, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21:79. https://doi.org/10.1186/s13075-019-1856-4.

Download references

Author information

Correspondence to Yoshiya Tanaka.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark